Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis

With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a growing survivor population that might be at risk for late mortality from non-LCH causes, including second primary malignancies (SPMs). We undertook a large study using the Surveillance, Epidemiology, and End...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2023-03, Vol.126, p.107032-107032, Article 107032
Main Authors: Goyal, Gaurav, Parikh, Richa, Richman, Joshua, Abeykoon, Jithma P., Morlote, Diana, Go, Ronald S., Bhatia, Smita
Format: Article
Language:English
Subjects:
Adult
Cause of Death
Child
Epidemiology
Female
Histiocytosis, Langerhans-Cell
Hodgkin Disease - complications
Humans
Infections
Late effects
Long term survival
Neoplasms, Second Primary - diagnosis
SEER Program
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a growing survivor population that might be at risk for late mortality from non-LCH causes, including second primary malignancies (SPMs). We undertook a large study using the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the patterns of SPMs and cause-specific mortality among individuals with LCH (2000–2016) from the US. We found an increased risk of SPMs in the cohort (standardized incidence ratio [SIR] 2.07). The pediatric group was at a high risk of developing Hodgkin lymphoma (SIR 60.93) and non-Hodgkin lymphoma (SIR 60.88). People with adult-onset LCH were found to have a high risk of developing miscellaneous malignant cancers (SIR 11.43), which primarily included myelodysplastic syndrome. Adults were also at a high risk of developing carcinoma in-situ of vulva at 2–11 months [SIR 62.72] and B-ALL at 60–119 months [SIR 66.29] after LCH diagnosis. Additionally, 5% and 1% of the patients developed prior or concomitant malignancies with LCH, respectively. The 5 yr overall survival (OS) was 96.6% for pediatric and 88.5% for adult LCH cohorts. Most common cause of death was infections in pediatric and SPMs in adult LCH. Our study highlights that despite advances in treatments, people with LCH have an increased mortality risk from non-LCH causes when compared with the general population, including a high risk of SPMs. •Long-term outcomes in Langerhans cell histiocytosis (LCH) are unknown at a population level.•We found an increased risk of second primary malignancies (SPMs) among LCH.•SPMs included lymphomas, MDS, and B-ALL.•Five-year overall survival was 96.6% for pediatric and 88.5% for adult LCH.•Most common cause of death in pediatric LCH was infections and in adults was SPMs.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2023.107032